Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSING: Tezepelumab in Eosinophilic Esophagitis
2022-001294-31Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Histologic response at Week 24. Started Sep 2022; status: active.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2022-001294-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001294-31.